- Conditions
- Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
- Interventions
- Elenestinib, Placebo
- Drug
- Lead sponsor
- Blueprint Medicines Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 534 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 12 more
Location Directory
Clinical trials in Cincinnati, Ohio
This page shows live ClinicalTrials.gov search results for Cincinnati, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10564
Shown on this page
12
Current sort
Recently updated
Location scope
Cincinnati, OH
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 889–900 of 10,564 matching trials in Cincinnati, OH.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
- Interventions
- Vepugratinib, Placebo, EV, Pembrolizumab
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 64
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 48 more
- Conditions
- Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Salivary Duct Carcinoma, Salivary Gland Adenocarcinoma, NOS, Salivary Gland Basal Cell Adenocarcinoma, Stage III Major Salivary Gland Cancer AJCC v7
- Interventions
- enzalutamide
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 287
- States / cities
- Anchorage, Alaska • Anaheim, California • Baldwin Park, California + 201 more
- Conditions
- Narcolepsy Type 1
- Interventions
- ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 22
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Ulcerative Colitis, Ulcerative Colitis Chronic
- Interventions
- Eltrekibart, Mirikizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 46
- States / cities
- Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 35 more
- Conditions
- Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Palbociclib, Temozolomide, Irinotecan, Topotecan, Cyclophosphamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more
- Conditions
- Birth Outcomes, Safety, Adverse Event Following Immunization
- Interventions
- mRNA COVID-19 vaccine, IIV4 (quadrivalent inactivated influenza vaccine)
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 2 more
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 524 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 28
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 22 more
- Conditions
- Cystic Fibrosis, Non-CF Bronchiectasis
- Interventions
- Xenon
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 5 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Inappropriate Sinus Tachycardia, Postural Tachycardia Syndrome
- Interventions
- AtriCure Commercially Available Devices
- Device
- Lead sponsor
- AtriCure, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Palo Alto, California • Redwood City, California + 9 more
- Conditions
- Obesity, Overweight
- Interventions
- LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 49
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more
- Conditions
- Cystic Fibrosis
- Interventions
- Initiation of CFTR Modulator
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Charlottesville, Virginia • Madison, Wisconsin